Teva Pharmaceutical Industries (TEVA) Work In Process (2009 - 2018)

Teva Pharmaceutical Industries has disclosed Work In Process across 10 years of filings, most recently posting $148.0 million for Q4 2018.

• Quarterly Work In Process fell 75.21% year-over-year to $148.0 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $148.0 million (down 75.21% YoY) and the FY2018 annual result came in at $148.0 million, down 75.21% from the prior year.
• Work In Process eased to $148.0 million in Q4 2018, from $609.0 million in the prior quarter.
• Over five years, Work In Process peaked at $646.0 million in Q1 2018 and troughed at $148.0 million in Q4 2018.
• A 5-year average of $495.9 million and a median of $601.0 million in 2017 frame the typical range for Work In Process.
• Annual changes were most pronounced in 2016 — Work In Process surged 189.25% — and 2018, when it plunged 75.21%.
• Tracing TEVA's Work In Process over 5 years: stood at $638.0 million in 2014, then plunged by 70.85% to $186.0 million in 2015, then jumped by 189.25% to $538.0 million in 2016, then advanced by 10.97% to $597.0 million in 2017, then tumbled by 75.21% to $148.0 million in 2018.
• Business Quant data shows TEVA's Work In Process at $148.0 million in Q4 2018, $609.0 million in Q3 2018, and $605.0 million in Q2 2018.